Search

Researchers at Johns Hopkins University have made advancements in the treatment of solid cancers using alpha-particle radionuclide-antibody conjugates. These conjugates are being evaluated against tumors that express moderate-to-low levels of targeted markers. To maintain efficacy, the researchers have developed carrier-cocktails that deliver a fraction of the radioactivity to different tumor regions than those affected by the antibodies. In vitro and in vivo studies showed that these carrier-cocktails significantly improved killing efficacy and decreased tumor volumes, as well as eliminated the formation of spontaneous metastases. The researchers concluded that tumor-agnostic carrier-cocktails enhance the therapeutic efficacy of existing treatments. [Extracted from the article]

Researchers at the University of Melbourne in Australia have developed a new therapy for targeting tumors using alpha particle emitting actinium-225. The researchers designed and synthesized a new chelator that can be conjugated to antibodies and forms stable complexes with actinium-225. They successfully modified a monoclonal antibody that binds to carbonic anhydrase IX, an enzyme overexpressed on the surface of certain cancers, and demonstrated a highly significant therapeutic response in a mouse xenograft model. The researchers believe that this new chelator could be used to modify other antibodies, providing a versatile platform for actinium-225 based therapeutics. [Extracted from the article]

A patent application titled "Systems, Apparatus And Methods For Separating Actinium, Radium, And Thorium" has been published online. The inventors propose methods for separating these radioactive elements from each other and from other metals. The patent application describes various techniques, including the use of weak acid solutions, selective precipitants, and chromatographic purification. The invention aims to improve the production and purification of desirable radioisotopes for medical applications, such as cancer treatment. The patent application provides detailed descriptions of the methods and apparatus involved. [Extracted from the article]

The University of British Columbia has been issued a patent for systems, apparatus, and methods for separating actinium, radium, and thorium. The patent describes the use of radionuclides, such as radium-225, radium-223, actinium-225, and bismuth-213, for the treatment of tumors and cancers. The invention involves a method of separating thorium from actinium and/or radium, as well as a method of separating actinium or radium from thorium. The patent also discusses the production and purification of desirable radioisotopes, including thorium, actinium, and radium. The methods involve the use of selective precipitants and chromatographic purification techniques. [Extracted from the article]

Serva Energy's novel production method of the rare cancer-killing medical isotope Actinium-225 (Ac-225) has been validated by the MIT Nuclear Research Laboratory. This milestone in Serva's development of commercial quantities of Ac-225 is crucial for next-generation Targeted Alpha Therapies. Serva's technology transforms Radium-226 into Ac-225, potentially providing sufficient quantities to meet the demand for Ac-225-based therapies. This innovative approach also reduces nuclear waste by using it as fuel for the reactor. [Extracted from the article]

We investigated the impact of Actinium-227 and daughters in the radiopharmaceutical quality control evaluation of an Actinium labeled peptide under good manufacturing practices. Keywords: St. Louis; State:Missouri; United States; North and Central America; Actinium; Actinoid Series Elements; Alpha Particle; Cancer; Drugs and Therapies; Health and Medicine; Indicators and Reagents; Oncology; Physics; Radiopharmaceuticals EN St. Louis State:Missouri United States North and Central America Actinium Actinoid Series Elements Alpha Particle Cancer Drugs and Therapies Health and Medicine Indicators and Reagents Oncology Physics Radiopharmaceuticals 1126 1126 1 09/11/23 20230915 NES 230915 2023 SEP 12 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- New research on Cancer is the subject of a report. [Extracted from the article]

Keywords: Actinium; Actinoid Series Elements; Drugs and Therapies; Emerging Technologies; Nanomaterials; Nanotechnology; Therapy EN Actinium Actinoid Series Elements Drugs and Therapies Emerging Technologies Nanomaterials Nanotechnology Therapy 1127 1127 1 07/03/23 20230707 NES 230707 2023 JUL 4 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Current study results on nanomaterials have been published. Actinoid Series Elements, Drugs and Therapies, Emerging Technologies, Nanomaterials, Nanotechnology, Therapy, Actinium. [Extracted from the article]

The Department of Energy (DOE) Office of Science's Isotope Program is developing and marketing novel radioactive isotopes for targeted alpha therapy. Keywords: Actinium; Actinoid Series Elements; Alkaline Earth Metals; DOE/US Department of Energy; Department Of Energy; Energy; Isotopes; Radioactive Elements; Radioisotopes; Radium; Therapy EN Actinium Actinoid Series Elements Alkaline Earth Metals DOE/US Department of Energy Department Of Energy Energy Isotopes Radioactive Elements Radioisotopes Radium Therapy 1349 1349 1 06/19/23 20230620 NES 230620 2023 JUN 20 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Targeted alpha therapy can destroy cancerous cells without harming healthy cells. [Extracted from the article]

The article discusses a study by researchers at Los Alamos National Laboratory (LANL) related to improving understanding of actinium-225. It mentions that according to the study actinium in solutions of concentrated hydrochloric acid is surrounded by three atoms of chlorine and six molecules of water. It also mentions that the U.S. Nuclear Regulatory Commission (NRC) has issued a notice of violation and proposed civil penalty to International Cyclotron.

This article reports that NorthStar Nuclear Medicine Inc. has signed a pact with Idaho National Laboratory (INL) to develop and use the lab's Medical Actinium for Therapeutic Treatment process, a patented invention for the separation of actinium-225 (Ac-225) from unused reactor fuel. Information is presented on the unused reactor fuel at INL. The life span of Ac-225 is discussed, as well as its potential use as an anticancer agent.